Michael Albert, MD

Atrial Fibrillation

CLOSURE-AF Results Question Just How Good LAAO Is

There’s been some serious debate over the last few years about whether or not left atrial appendage occlusion is actually the best stroke prevention option for high-risk AFib patients, and the latest results from the CLOSURE-AF trial suggest it might not be as effective as previously thought.

• LAAO is widely used for AFib patients at high risk of stroke and bleeding based on the premise that while anticoagulation is effective, it often leads to internal bleeding.
• Current guidelines provide only modest support for LAAO in high-risk populations (class 2b in U.S., class IIb in Europe), reflecting limited randomized trial evidence.
• This is especially important since patients with bleeding history are typically excluded from major trials.

To bring closure to the LAAO debate, CLOSURE-AF enrolled 912 patients with CHA2DS2-VASc scores  ≥2 and HAS-BLED scores ≥3 and randomized them to receive either LAAO (Amplatzer Amulet/Watchman FLX) or physician-directed standard care over a median 3-year follow-up, leading to results that have many non-interventionists saying “I told you so…”

• LAAO failed noninferiority for the composite primary endpoint of stroke, systemic embolism, cardiovascular/unexplained death, or major bleeding.
• Event rates were much better with standard anticoagulation: 16.83 per 100 person-years with LAAO versus 13.27 with medical therapy (aHR 1.28).
• Individual endpoint components occurred at similar rates, though the trial lacked statistical power for those analyses.

While these results might be shocking to some, there are several nuances to consider, and failing noninferiority doesn’t mean throwing LAAO out with the bathwater.

• CLOSURE-AF enrollment began in 2018 when operators had less experience, and the trial used mixed devices including some that are no longer marketed.
• The high-risk population mirrors trials like Amulet IDE, PRAGUE-17, and the ongoing CONFORM trial, representing patients for whom LAAO is approved and indicated.

The Takeaway

The CLOSURE-AF trial provides much-needed RCT evidence in bleeding-risk patients typically excluded from major trials, filling a critical knowledge gap in guideline development for who should get LAAO. It’s also a reminder that a procedure like LAAO is a specialized tool more than a catch-all for high-risk AFib patients.

How Vista AI Helps Solve the Technologist Shortage

Fewer than 2% of MRI scanners are routinely used for cardiac imaging—mainly due to a shortage of trained technologists amid rising demand. Vista AI addresses this challenge by automating CMR scanning, empowering technologists of all experience levels to deliver high-quality cardiac exams consistently and efficiently.

5,600 Ways to Improve Your Cardiac Ultrasound Workflow

AI-powered measurements can enhance the way you acquire and interpret cardiac ultrasound. Learn how AI-powered ultrasound can help you overcome everyday limitations in echo. Read Siemens Healthineers’ white paper on how its AI software provides 5,600+ automated measurements to help improve workflow efficiency, consistency, and clinical confidence.

Identify and Treat Cardiovascular Disease

Complex care pathways make getting patients to the next step a challenge. See how Tempus Next, an AI enabled care pathway platform, helps providers identify and reduce under treatment in cardiovascular disease by adding an intelligent layer onto their routinely generated EHR data.

The Wire

• Heartflow Shows Off Plaque Staging: Heartflow presented late-breaking FISH&CHIPS Study data at AHA 2025 that help validate its AI-powered Heartflow Plaque Analysis with Plaque Staging software. The validation study found that patients in the highest total plaque volume stage had 5x greater risk of major cardiovascular events versus the lowest stage (HR 5.10) over a median 3.3-year follow-up. Higher plaque stages independently predicted cardiovascular death and myocardial infarction, remaining significant after adjusting for stenosis, FFR-CT, and risk factors.

• Milestone’s PSVT Spray: Milestone Pharmaceuticals unveiled new pooled data at AHA analyzing its etripamil nasal spray across multiple PSVT clinical trials. Tested across 622 patients, self-administered etripamil demonstrated consistent efficacy with a median conversion time of 18.5 minutes, 59.6% conversion to sinus rhythm by 30 minutes, and up to 75.1% by 60 minutes. Safety data also showed predominantly mild, transient, nasal-localized adverse events, with only 1.4% test-dose failures. The FDA is currently reviewing etripamil’s NDA with a PDUFA target date of December 13, 2025.

• AHA’s AI Guidance: The AHA recently released a science advisory urging health systems to adopt clear governance frameworks for healthcare AI deployment. Despite hundreds of FDA-cleared AI tools, only a fraction undergo rigorous clinical evaluation and just 61% of hospitals validate tools on local data pre-deployment. The advisory proposes four guiding principles to help address this: strategic alignment, ethical evaluation, usefulness/effectiveness, and financial performance.

• AZ’s Baxdrostat Results: AstraZeneca announced positive Phase 3 Bax24 trial results showing that its BP drug, baxdrostat achieved a significant SBP reduction in patients undergoing treatment for 12 weeks. Researchers examined 217 patients randomized to receive either placebo or 2mg baxdrostat added to standard care and found that 71% of baxdrostat patients achieved target blood pressure (<130 mmHg) versus 17% on placebo. The drug was generally well-tolerated and showed clinically meaningful reductions across nighttime and seated blood pressure measurements.

• AccurKardia’s AK+ Guard Algorithm: A poster presentation at AHA about AccurKardia’s AK+ Guard algorithm suggests automated hyperkalemia screening in high-risk ambulatory populations could be possible using an ECG algorithm. Researchers conducted a retrospective study of 184k ECG-potassium pairs from Sharp HealthCare and found that the algorithm demonstrated 82.3% sensitivity, 82.5% specificity, and an AUROC of 0.903, with AI scores increasing stepwise across hyperkalemia severity categories.

• Anumana’s AHA Data: Anumana presented new AI cardiovascular diagnostic data during an AHA late-breaker that reinforced its AI’s potential for earlier cardiovascular disease detection. Analyzing 14k+ participants across three major cohorts, researchers found Anumana’s ECG-AI significantly improved heart failure prediction when combined with PREVENT-HF clinical risk models, reclassifying 12.5% of individuals into higher-risk categories. Patients with positive ECG-AI results were also 20x more likely to develop HF within three years.

• Kardigan’s Ataciguat Shows Promise: Kardigan announced positive Phase 2 results for ataciguat, its investigational oral drug for moderate calcific AS. The trial showed ataciguat slowed aortic valve calcium progression, improving cardiac output, LVEF, and reducing valve resistance compared to placebo. With over 3.4M U.S. patients having no approved treatments beyond “watchful waiting” until valve replacement becomes necessary, ataciguat could be a potential first-in-class disease-modifying therapy.

• AISAP’s Ghana Initiative: AISAP announced a new initiative to deploy its FDA-cleared AI cardiac diagnosis platform in Ghana, in a plan to address the country’s severe cardiologist shortage (fewer than 30 serving 35M people). Through partnership with G-ACT Foundation, the cloud-based POCAD platform delivers specialist-level cardiac diagnostics to frontline clinicians using portable ultrasound devices. Trained on 300k+ echocardiogram studies, the system provides real-time interpretation with urgency scoring and quality assurance.

• Withings BeamO Clearance: Withings received FDA clearance for its BeamO health device that combines electrocardiogram, digital stethoscope, and thermometer capabilities. The device enables at-home monitoring of heart, lung, and body temperature and syncs with the Withings app via Wi-Fi/Bluetooth, allowing secure data sharing with physicians through HealthLink for enhanced telemedicine consultations. Withings hopes BeamO will help with carrying out teleconsultations in medical deserts or the absence of a general practitioner.

• CONFIRM2 and Plaque Stratification: Cleerly presented another analysis from its CONFIRM2 Registry data at AHA that suggests its AI-QCT software can accurately stratify patients by plaque burden and CV risk. The subanalysis examined 6.5k patients (51.6% female) over 4.4 years who underwent CCTA with AI-QCT and found that adding AI-QCT to ESC risk scores improved MACE and death/MI prediction. Notably, 78% of symptomatic patients had very-low/low likelihood of obstructive CAD, yet AI-QCT still successfully stratified their CV risk.

• Philips’ CV Workspace Clearance: Philips received FDA 510(k) clearance for its cloud-hosted Cardiovascular Workspace with SaaS deployment on HealthSuite. The cloud-based solution enables health systems to accelerate AI adoption, automate analysis, documentation, and reporting while providing secure remote access to cardiovascular imaging and patient data. The platform integrates with Philips’ existing PACS HealthSuite to deliver connected cardiovascular care with faster AI-enabled tools and workflow insights.

Cracking the Code of ECG Analysis with Monebo’s AI Genetic Algorithm

How do you teach a computer to recognize the complex patterns in an ECG signal? Discover how Monebo found the answer by blending human expertise and a little evolutionary magic in this article that breaks down the advantages of genetic algorithms in ECG analysis.

What Every Cardiologist Needs to Watch for in Heart Failure

Patients with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) face a high risk of hospitalization for heart failure and cardiovascular death, even with guideline-directed medical treatment. Hear from Bayer’s Dr. Alanna Morris-Simon as she shares common heart failure signs to look out for.

PIA’s Post-Processing Solution

Advanced cardiac imaging often calls for a time-consuming post-processing step, requiring costly software, hardware, and training. See how PIA provides this post-processing at lower cost, improved consistency, and greater efficiency.

The Resource Wire

• From CPACS to CVIS: Cardiovascular imaging has come a long way from CPACS. Explore the evolution of cardiology image and data management in this Merge executive brief, and see what makes CVIS such a significant advancement.

• The Largest Registry on Plaque Analysis in CAD: What if 50% of your CCTA patients could benefit from an adjustment to their treatment plan? Read more about Heartflow’s DECIDE registry that demonstrates how Heartflow Plaque Analysis using its Plaque Staging software empowers physicians with clinical insights that lead to real-world impact.

• GLS Analysis of Us2.ai’s Fully-Automated Software: Ten years after the first head-to-head comparison of 2D echocardiography, the latest review suggests Us2.ai is among the easiest to use and integrate. Read the study to learn about how Us2.ai’s software requires zero operator input, operates without human intervention, and leads to high agreement with traditional semi-automated speckle- tracking software solutions.

• Assessing CAD with Circle CVI: Did you know that Circle CVI offers a suite of cardiac CT tools for the assessment of coronary artery disease? See how Circle combines heart function segmentation, automated plaque analysis, CAC scoring, reporting, and viewing in a single dedicated Cardiac CT package.

• Explore Vitrea Advanced Visualization: Discover Canon Medical Healthcare IT’s suite of advanced imaging workflows designed to increase efficiency in cardiovascular imaging, and facilitate the assessment, diagnosis, and treatment of cardiovascular diseases. These cutting-edge tools support the delivery of faster, more accurate care while integrating seamlessly into clinical workflow.

The Industry Wire

1. Historic shutdown ends, ACA subsidies in limbo.
2. U.S. bishops ban transgender surgeries at Catholic hospitals.
3. Listening to music daily could help prevent dementia.
4. ‘White Lotus’ sparks interest in anxiety pills.
5. Ultra-processed food consumption linked to pre-cancerous growths.
6. Providence’s operations inch into positive territory during Q3.
7. HPAIV associated with Southern Elephant seal decline.
8. DEA to publish 4th extension of telehealth prescribing rule.
9. Ascension’s VC arm backs wearables.
10. Aetna tones down Medicare Advantage downcoding.